查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401902

到 2030 年藥物傳輸奈米藥物的市場預測：按產品類型、模式、適應症、給藥途徑、最終用戶和地區進行全球分析

Nanomedicine for Drug Delivery Market Forecasts to 2030 - Global Analysis By Product Type (Nanoparticles, Nanoshells, Nanodevices and Nanotubes), Modality (Treatments and Diagnostics), Indication, Route of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球用於給藥的奈米藥物市場規模為 1,976 億美元，預計在預測期內將以 13.5% 的複合年成長率成長，並在 2030 年達到 4,794 億美元。

被稱為「奈米醫學」的醫學領域利用奈米技術設備和專業知識來預防和治療多種疾病。奈米顆粒可以設計用於靶向特定細胞或組織，透過將其直接遞送至預定部位來減少副作用並提高藥物療效。奈米顆粒可以延長藥物在體內的循環時間，使藥物持續釋放，減少用藥給藥。

根據美國癌症協會估計，2023 年美國女性中將診斷出 297,790 例新的侵襲性乳癌病例。奈米顆粒、奈米載體和其他奈米級藥物傳遞平台具有獨特的特性，可增強對藥物穩定性、溶解度、生物利用度和釋放動力學的控制。

慢性病增加

糖尿病、心臟病和癌症等慢性疾病變得越來越普遍。基於奈米醫學的藥物傳輸系統在提高治療藥物對抗這些疾病的功效方面顯示出了有希望的結果。由於奈米粒子能夠靶向特定細胞和組織並將藥物直接輸送到作用部位，因此慢性疾病的治療變得更具吸引力。隨著這些疾病的流行，對奈米藥物在藥物傳輸方面的需求不斷增加。

安全問題

雖然奈米醫學有很多好處，但也有人擔心奈米粒子的安全性。奈米粒子的小尺寸和特殊的物理化學性質增加了意想不到的生物相互作用和毒性的可能性。奈米顆粒暴露和在體內累積的長期影響仍在研究中。奈米醫學產品的市場接受度可能會受到安全問題的影響。

影像和診斷技術的進步

奈米醫學對於電腦斷層掃描 (CT)、正子斷層掃描 (PET) 和磁振造影(MRI) 等診斷影像方式至關重要。透過設計攜帶成像劑的奈米顆粒，可以改善疾病檢測和可視化。將診斷和治療功能整合到奈米顆粒中可以實現將診斷和治療相結合的治療診斷應用。成像和診斷技術的開拓推動了奈米藥物傳輸市場的擴張。

製造可擴展性

含有奈米藥物的產品可能涉及複雜的製造過程，需要專門的設施和機械。在提高產量的同時保持最終產品的成本效益、一致性和品質時，需要克服許多障礙。製造奈米醫學產品通常涉及複雜且耗時的奈米顆粒合成、精製和表徵過程。生產具有精確尺寸、型態和表面特性的奈米粒子需要先進的技術和專業知識。因此，製造規模化是阻礙市場需求的主要因素。

COVID-19 的影響

COVID-19 大流行對藥物輸送奈米醫學市場產生了重大影響。全球供應鏈中斷導致基本成分短缺，並阻礙了奈米藥物的生產。由於面對面互動有限，新應用的臨床試驗面臨延誤和中斷，影響了研究進展。由於人們對標靶藥物輸送系統和遠端醫療解決方案的關注，市場需求發生了波動，凸顯了適應性強和精確的藥物傳遞機制的重要性。這場大流行加速了遠端醫療和遠端患者監護的採用，影響了對支持這些新醫療方法的藥物輸送系統的需求。

奈米殼產業預計將在預測期內成為最大的產業

預計奈米殼領域將佔據最大佔有率。這些是核殼奈米粒子，其中薄金屬殼（通常由銀或金製成）包圍介電核。由於它們的特殊結構，它們的光學特性、散射和吸收光的能力可以被精確控制。在藥物傳遞方面，奈米殼被設計用於攜帶治療劑並將其給藥到體內的特定標靶位點。可以調整其尺寸和表面特性，以最大限度地提高與生物組織的相互作用。此外，由於金屬外殼，它們可以對特定波長的光做出反應，這是標靶治療和控制藥物釋放的重要特性。

預計腫瘤學領域在預測期內將經歷最高的複合年成長率。

預計腫瘤疾病領域在預測期內將出現良好的成長。抗癌藥物最大限度地減少對健康組織的損害，並且能夠精確地靶向腫瘤。透過特異性辨識和結合癌細胞，這些奈米顆粒可以被設計來增強腫瘤部位的藥物累積。此外，這些奈米載體的特殊性質可以調節藥物的釋放，從而產生持久和有針對性的治療效果。由於尺寸小，奈米載體可以穿透腫瘤組織並到達常規藥物難以到達的區域。

佔有率最高的地區

在估計期間，北美佔據了最大的市場佔有率。對研發的大量投資和強大的衛生系統創造了有利於奈米技術創新發展的氛圍。主要生物技術和製藥公司的存在促進了團隊合作，並促進了先進藥物輸送系統的開發。建立了創新和發現文化的學術機構和研究中心不斷為該地區奈米醫學的技術突破做出貢獻。

複合年成長率最高的地區：

歐洲專注於研究和開發，已成為奈米醫學藥物傳輸的重要中心。這項創新由德國、英國、瑞士等國家引領，為科學研究和技術發展提供了豐富的環境。該地區專注於尖端方法，特別強調利用奈米技術的精準醫療和個人化治療。歐洲是先進藥物傳輸系統發展的驅動力，在全球奈米醫學市場中發揮關鍵作用。

免費客製化服務：

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章依產品類型分類的全球藥物傳輸奈米醫學市場

  • 介紹
  • 奈米顆粒
    • 金屬和金屬氧化物奈米顆粒
    • 脂質體
    • 水凝膠奈米粒子
    • 聚合物和聚合物藥物綴合物
    • 樹狀聚合物
    • 無機奈米粒子
  • 奈米殼
  • 奈米裝置
  • 奈米管

第6章全球藥物傳輸奈米醫學市場：依方式分類

  • 介紹
  • 治療
  • 診斷

第7章全球藥物傳輸奈米醫學市場：依適應症分類

  • 介紹
  • 感染疾病
  • 整形外科疾病
  • 腫瘤性疾病
  • 心血管疾病
  • 泌尿系統疾病
  • 神經系統疾病
  • 免疫疾病
  • 眼科疾病
  • 其他適應症

第8章全球藥物傳輸奈米藥物市場：依給藥途徑

  • 介紹
  • 胃腸外的
  • 口服
  • 吸入
  • 局部的

第9章全球藥物傳輸奈米醫學市場：依最終用戶分類

  • 介紹
  • 專科診所
  • 醫院
  • 其他最終用戶

第10章全球藥物傳輸奈米醫學市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Camurus AB
  • Celgene, Inc.
  • EyePoint Pharmaceuticals
  • EnColl Corporation
  • Cytimmune Sciences, Inc.
  • Ceramisphere Health Pty Limited
  • Cristal Therapeutics
  • Aquanova AG
  • BlueWillow Biologics
  • AbbVie Inc.
  • Amgen Foundation
  • Abbott
  • Cadila Pharmaceuticals
  • Novartis AG
  • Johnson & Johnson Services
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
Product Code: SMRC24422

According to Stratistics MRC, the Global Nanomedicine for Drug Delivery Market is accounted for $197.6 billion in 2023 and is expected to reach $479.4 billion by 2030 growing at a CAGR of 13.5% during the forecast period. The field of medicine known as "nanomedicine" employs instruments and expertise in nanotechnology to prevent and cure various illnesses. Nanoparticles can be engineered to target specific cells or tissues, reducing side effects and increasing the drug's effectiveness by delivering it directly to the intended site. Nanoparticles can extend a drug's circulation time in the body, allowing for a sustained release of medication and reducing the frequency of dosing.

According to American Cancer Society, it is estimated in 2023, about 297,790 new cases of invasive breast cancer will be diagnosed in women in U.S. Nanoparticles, nanocarriers, and other nanoscale drug delivery platforms offer unique properties that enhance drug stability, solubility, bioavailability, and control over release kinetics.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

Chronic illnesses, including diabetes, heart disease, and cancer, are becoming more common. Nanomedicine-based drug delivery systems have shown promising results in improving the efficacy of therapeutic agents for these conditions. Treating chronic diseases has become more appealing for nanoparticles due to their capacity to target particular cells or tissues and deliver drugs directly to the site of action. The need for nanomedicine in drug delivery rises with the prevalence of these diseases.

Restraint:

Safety concerns

While nanomedicine offers numerous benefits, there are concerns regarding the safety of nanoparticles. Nanoparticles' small size and special physicochemical characteristics raise the possibility of unforeseen biological interactions and toxicity. The long-term effects of nanoparticle exposure and accumulation in the body are still being studied. The market's acceptance of nanomedicine products can be affected by safety concerns.

Opportunity:

Technological advancements in imaging and diagnostics

In diagnostic imaging methods like computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI), nanomedicine is essential. It is possible to engineer nanoparticles to carry imaging agents, improving disease detection and visualization. The integration of diagnostic and therapeutic functions in nanoparticles allows for theranostic applications, where diagnosis and treatment can be combined. The expansion of the nanomedicine drug delivery market has been facilitated by developments in imaging and diagnostics.

Threat:

Manufacturing scalability

Products involving nanomedicines can have complicated manufacturing processes requiring specialized facilities and machinery. There are many obstacles to overcome when increasing production while preserving the cost-effectiveness, consistency, and quality of the final product. The production of nanomedicine products frequently entails the complex and time-consuming processes of synthesizing, purifying, and characterizing nanoparticles. Advanced technologies and expertise are needed to produce nanoparticles with precise size, shape, and surface characteristics. Therefore, manufacturing scalability is a significant factor hampering market demand.

COVID-19 Impact

The COVID-19 pandemic profoundly affected the nanomedicine for drug delivery market. Disruptions in the global supply chain led to shortages of essential components, hindering the production of nanomedicine. Clinical trials for new applications faced delays or halts due to restrictions on in-person interactions, impacting research progress. Market demand fluctuated as the focus turned toward targeted drug delivery systems and remote healthcare solutions, highlighting the importance of adaptable and precise drug delivery mechanisms. The pandemic accelerated the adoption of telemedicine and remote patient monitoring, influencing the demand for drug delivery systems that support these new healthcare approaches.

The nanoshells segment is expected to be the largest during the forecast period

The nanoshells segment is estimated to hold the largest share. These are core-shell nanoparticles, with a thin metallic shell (usually made of silver or gold) encircling a dielectric core. Because of their special structure, their optical characteristics, namely, their capacity to scatter and absorb light, can be precisely controlled. Nanoshells are designed to carry and administer therapeutic agents to particular target areas within the body when it comes to drug delivery. It is possible to adjust their size and surface characteristics to maximize interactions with biological tissues. Additionally, they can also react to particular light wavelengths due to their metallic shell, which is an essential characteristic for targeted therapy and controlled drug release.

The oncological diseases segment is expected to have the highest CAGR during the forecast period

The oncological diseases segment is anticipated to have lucrative growth during the forecast period. They minimize damage to healthy tissues and enable precise targeting of tumors. By specifically recognizing and binding to cancer cells, these nanoparticles can be engineered to enhance the drug's accumulation at the tumor site. Furthermore, these nanocarriers' special qualities allow for regulated drug release, resulting in long-lasting and targeted therapeutic effects. Because of their small size, they can penetrate tumor tissues and reach places that may be difficult for conventional medications to reach.

Region with largest share:

North America commanded the largest market share during the extrapolated period. Significant investments in research and development, in conjunction with a strong healthcare system, create an atmosphere that is favourable to innovative developments in nanotechnology. Leading biotech and pharmaceutical companies is present, which encourages teamwork and leads to the development of advanced drug delivery systems. Establishing a culture of innovation and discovery, academic institutions and research centers consistently contribute to technological breakthroughs in nanomedicine in this region.

Region with highest CAGR:

Europe is expected to witness profitable growth over the projection period, owing to its strong focus on research and development, Europe is a prominent hub for nanomedicine in drug delivery. This innovation is driven by nations like Germany, the UK, and Switzerland, which provide a rich environment for scientific research and technological development. The region is focused on cutting-edge methods, with a particular emphasis on precision medicine and customized treatments utilizing nanotechnology. Europe as a driving force in the evolution of advanced drug delivery systems, making it a crucial player in the global nanomedicine market.

Key players in the market:

Some of the key players in the Nanomedicine for Drug Delivery Market include Camurus AB, Celgene, Inc., Eye Point Pharmaceuticals, EnColl Corporation, Cytimmune Sciences, Inc., Ceramisphere Health Pty Limited, Cristal Therapeutics, Aquanova AG, Blue Willow Biologics, AbbVie Inc., Amgen Foundation, Abbott, Cadila Pharmaceuticals , Novartis AG, Johnson & Johnson Services, Pfizer Inc., F. Hoffmann-La Roche Ltd and Eli Lilly and Company.

Key Developments:

In Dec 2022, Eli Lilly and Company and EVA Pharma announced a collaboration to deliver a sustainable supply of high-quality, affordable human and analogue insulin to at least one million people living with type 1 and type 2 diabetes in low-to middle income.

In Aug 2022, Abbott and WeightWatchers announced a strategic partnership that will help people living with diabetes better understand and manage their diabetes and weight.

In June 2022, Pfizer announces Strategic Collaboration with Truveta to Accelerate Safety Insights in Real Time. Truveta will provide Pfizer with an unprecedented data platform for research. The data collected by Truveta are always flowing, providing the most up-to-date picture of U.S. health.

Product Types Covered:

  • Nanoparticles
  • Nanoshells
  • Nanodevices
  • Nanotubes

Modalities Covered:

  • Treatments
  • Diagnostics

Indications Covered:

  • Infectious Diseases
  • Orthopedic Disorders
  • Oncological Diseases
  • Cardiovascular Diseases
  • Urological Diseases
  • Neurological Diseases
  • Immunological Diseases
  • Ophthalmological Diseases
  • Other Indications

Route of Administrations Covered:

  • Parenteral
  • Oral
  • Inhalation
  • Topical

End Users Covered:

  • Specialty Clinics
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Nanomedicine for Drug Delivery Market, By Product Type

  • 5.1 Introduction
  • 5.2 Nanoparticles
    • 5.2.1 Metal and Metal Oxide Nanoparticles
    • 5.2.2 Liposomes
    • 5.2.3 Hydrogel Nanoparticles
    • 5.2.4 Polymers and Polymer Drug Conjugates
    • 5.2.5 Dendrimers
    • 5.2.6 Inorganic Nanoparticles
  • 5.3 Nanoshells
  • 5.4 Nanodevices
  • 5.5 Nanotubes

6 Global Nanomedicine for Drug Delivery Market, By Modality

  • 6.1 Introduction
  • 6.2 Treatments
  • 6.3 Diagnostics

7 Global Nanomedicine for Drug Delivery Market, By Indication

  • 7.1 Introduction
  • 7.2 Infectious Diseases
  • 7.3 Orthopedic Disorders
  • 7.4 Oncological Diseases
  • 7.5 Cardiovascular Diseases
  • 7.6 Urological Diseases
  • 7.7 Neurological Diseases
  • 7.8 Immunological Diseases
  • 7.9 Ophthalmological Diseases
  • 7.10 Other Indications

8 Global Nanomedicine for Drug Delivery Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Parenteral
  • 8.3 Oral
  • 8.4 Inhalation
  • 8.5 Topical

9 Global Nanomedicine for Drug Delivery Market, By End User

  • 9.1 Introduction
  • 9.2 Specialty Clinics
  • 9.3 Hospitals
  • 9.4 Other End Users

10 Global Nanomedicine for Drug Delivery Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Camurus AB
  • 12.2 Celgene, Inc.
  • 12.3 EyePoint Pharmaceuticals
  • 12.4 EnColl Corporation
  • 12.5 Cytimmune Sciences, Inc.
  • 12.6 Ceramisphere Health Pty Limited
  • 12.7 Cristal Therapeutics
  • 12.8 Aquanova AG
  • 12.9 BlueWillow Biologics
  • 12.10 AbbVie Inc.
  • 12.11 Amgen Foundation
  • 12.12 Abbott
  • 12.13 Cadila Pharmaceuticals
  • 12.14 Novartis AG
  • 12.15 Johnson & Johnson Services
  • 12.16 Pfizer Inc.
  • 12.17 F. Hoffmann-La Roche Ltd
  • 12.18 Eli Lilly and Company

List of Tables

  • Table 1 Global Nanomedicine for Drug Delivery Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Nanomedicine for Drug Delivery Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Nanomedicine for Drug Delivery Market Outlook, By Nanoparticles (2021-2030) ($MN)
  • Table 4 Global Nanomedicine for Drug Delivery Market Outlook, By Metal and Metal Oxide Nanoparticles (2021-2030) ($MN)
  • Table 5 Global Nanomedicine for Drug Delivery Market Outlook, By Liposomes (2021-2030) ($MN)
  • Table 6 Global Nanomedicine for Drug Delivery Market Outlook, By Hydrogel Nanoparticles (2021-2030) ($MN)
  • Table 7 Global Nanomedicine for Drug Delivery Market Outlook, By Polymers and Polymer Drug Conjugates (2021-2030) ($MN)
  • Table 8 Global Nanomedicine for Drug Delivery Market Outlook, By Dendrimers (2021-2030) ($MN)
  • Table 9 Global Nanomedicine for Drug Delivery Market Outlook, By Inorganic Nanoparticles (2021-2030) ($MN)
  • Table 10 Global Nanomedicine for Drug Delivery Market Outlook, By Nanoshells (2021-2030) ($MN)
  • Table 11 Global Nanomedicine for Drug Delivery Market Outlook, By Nanodevices (2021-2030) ($MN)
  • Table 12 Global Nanomedicine for Drug Delivery Market Outlook, By Nanotubes (2021-2030) ($MN)
  • Table 13 Global Nanomedicine for Drug Delivery Market Outlook, By Modality (2021-2030) ($MN)
  • Table 14 Global Nanomedicine for Drug Delivery Market Outlook, By Treatments (2021-2030) ($MN)
  • Table 15 Global Nanomedicine for Drug Delivery Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 16 Global Nanomedicine for Drug Delivery Market Outlook, By Indication (2021-2030) ($MN)
  • Table 17 Global Nanomedicine for Drug Delivery Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 18 Global Nanomedicine for Drug Delivery Market Outlook, By Orthopedic Disorders (2021-2030) ($MN)
  • Table 19 Global Nanomedicine for Drug Delivery Market Outlook, By Oncological Diseases (2021-2030) ($MN)
  • Table 20 Global Nanomedicine for Drug Delivery Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 21 Global Nanomedicine for Drug Delivery Market Outlook, By Urological Diseases (2021-2030) ($MN)
  • Table 22 Global Nanomedicine for Drug Delivery Market Outlook, By Neurological Diseases (2021-2030) ($MN)
  • Table 23 Global Nanomedicine for Drug Delivery Market Outlook, By Immunological Diseases (2021-2030) ($MN)
  • Table 24 Global Nanomedicine for Drug Delivery Market Outlook, By Ophthalmological Diseases (2021-2030) ($MN)
  • Table 25 Global Nanomedicine for Drug Delivery Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 26 Global Nanomedicine for Drug Delivery Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 27 Global Nanomedicine for Drug Delivery Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 28 Global Nanomedicine for Drug Delivery Market Outlook, By Oral (2021-2030) ($MN)
  • Table 29 Global Nanomedicine for Drug Delivery Market Outlook, By Inhalation (2021-2030) ($MN)
  • Table 30 Global Nanomedicine for Drug Delivery Market Outlook, By Topical (2021-2030) ($MN)
  • Table 31 Global Nanomedicine for Drug Delivery Market Outlook, By End User (2021-2030) ($MN)
  • Table 32 Global Nanomedicine for Drug Delivery Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 33 Global Nanomedicine for Drug Delivery Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 34 Global Nanomedicine for Drug Delivery Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.